Redhill Biopharma Ltd (RDHL) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court PR...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041 PR Newswire TEL-AVIV, Israel...